skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis

Review

(2152) Views  (941) Full article downloads

Authors: Peter BB Jones, Douglas HN White

Published Date November 2010 Volume 2010:2 Pages 53 - 71
DOI: http://dx.doi.org/10.2147/OARRR.S9448

Peter BB Jones1,2, Douglas HN White2
1Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 2Rheumatology Department, Waikato Hospital, Hamilton, New Zealand

Abstract: Leflunomide is a disease-modifying antirheumatic drug (DMARD) that has been in routine clinical use for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis for a decade. In RA, clinical trials of up to two years’ duration showed that leflunomide monotherapy was equivalent to methotrexate in clinical and radiographic disease outcomes (tender and swollen joint counts, physician and patient global assessments, American College of Rheumatology and Disease Activity Score responses, slowing or halting of radiographic progression). In a number of studies, quality of life measurements indicated that leflunomide is superior to methotrexate. Leflunomide has been studied in combination with methotrexate and shows efficacy in patients only partly responsive to this agent. Recent trials have shown that leflunomide can be used safely with biologic DMARDs, including antitumor necrosis factor agents and rituximab as part of the treatment algorithm in place of methotrexate as a cotherapy. Leflunomide has demonstrated efficacy as a monotherapy in psoriatic arthritis, and it also has a beneficial effect in psoriasis. Postmarketing studies have shown that retention on treatment with leflunomide is equal to methotrexate and superior to other DMARDs. In general, its side effect profile is acceptable compared with other DMARDS, with nausea, diarrhea, and hair fall occurring commonly, but only rarely leading to discontinuation. Liver toxicity is the most significant problem in clinical use although it is uncommon. Peripheral neuropathy, hypertension, pneumonitis, and cytopenia occur more rarely. Leflunomide is contraindicated in pregnancy and should be used with caution in women during child-bearing years. In this review, the place of leflunomide in therapy is discussed and practical advice informed by evidence is given regarding dosing regimens, safety monitoring, and managing side effects. Leflunomide remains one of the most useful of the nonbiologic DMARDs.

Keywords: evidence-based practice, review, disease-modifying antirheumatic drugs, safety, efficacy, leflunomide, rheumatoid arthritis, psoriatic arthritis






Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Management strategies for pulmonary sarcoidosis
Association of periodontitis with rheumatoid arthritis and atherosclerosis: Novel paradigms in etiopathogeneses and management?
Advances in diagnostic and treatment options in patients with fibromyalgia syndrome
New and emerging therapies for the treatment of rheumatoid arthritis
Erratum - Intracellular heavy metal nanoparticle storage
Certolizumab in the long-term treatment of rheumatoid arthritis
The epidemiology and treatment of gout
Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio